Drug Interactions between cephalexin and chloramphenicol
This report displays the potential drug interactions for the following 2 drugs:
- cephalexin
- chloramphenicol
Interactions between your drugs
chloramphenicol cephalexin
Applies to: chloramphenicol and cephalexin
MONITOR: Limited, primarily in vitro, data suggest that chloramphenicol may antagonize the bactericidal activity of cephalosporins against certain clinical isolates of gram-negative rods, group B streptococci, and Staphylococcus aureus. This antagonism appears to occur against strains for which chloramphenicol is bacteriostatic, and has been demonstrated with cefoperazone, cefotaxime, and ceftriaxone. The proposed mechanism is inhibition of protein synthesis by chloramphenicol, resulting in less protein substrate for cephalosporins to act on as inhibitors of bacterial cell wall synthesis. The clinical relevance of these findings is unknown. Potential antagonism was suspected in two case reports of treatment failure in patients with gram-negative bacterial meningitis who received a cephalosporin in combination with chloramphenicol. One patient, a 2.5-month-old infant with Salmonella enteritidis group D meningitis, was subsequently treated with the cephalosporin (ceftazidime) alone and recovered uneventfully. The other, a 51-year-old male with Klebsiella pneumoniae meningitis, was subsequently treated with the cephalosporin (cefotaxime) plus amikacin and became afebrile, but later died with progressive neurologic disease. Autopsy findings were consistent with subacute spongiform encephalopathy (Creutzfeldt-Jakob disease).
MANAGEMENT: The manufacturers recommend to avoid concomitant use . However, if concurrent administration cannot be avoided, the possibility of antagonism should be considered, and patients should be monitored for altered therapeutic effect.
References (7)
- French GL, Ling TK, Davies DP, Leung DT (1985) "Antagonism of ceftazidime by chloramphenicol in vitro and in vivo during treatment of gram negative meningitis." Br Med J (Clin Res Ed), 291, p. 636-7
- Asmar BI, Prainito M, Dajani AS (1988) "Antagonistic effect of chloramphenicol in combination with cefotaxime or ceftriaxone." Antimicrob Agents Chemother, 32, p. 1375-8
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Cerner Multum, Inc. "Australian Product Information."
- Agencia Española de Medicamentos y Productos Sanitarios Healthcare (2008) Centro de información online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html
- Brown TH, Alford RH (1984) "Antagonism by chloramphenicol of broad-spectrum beta-lactam antibiotics against Klebsiella pneumoniae." Antimicrob Agents Chemother, 25, p. 405-7
- Brown TH, Alford RH (1985) "Failure of chloramphenicol and cefotaxime therapy in Klebsiella meningitis: possible role of antibiotic antagonism." South Med J, 78, p. 869-71
Drug and food interactions
cephalexin food
Applies to: cephalexin
ADJUST DOSING INTERVAL: Oral products containing zinc such as mineral supplements and multivitamins may interfere with the gastrointestinal absorption of cephalexin, ceftibuten or cephradine. In one pharmacokinetic study (n=12), concurrent administration of zinc sulfate (250 mg, single oral dose) and cephalexin (500 mg, single oral dose) decreased cephalexin maximum concentration (Cmax) and systemic exposure (AUC; 0-inf) by 31.05% and 27.4%, respectively. However, in the same study, when zinc sulfate was administered 3 hours after the cephalexin dose, no significant alteration in cephalexin pharmacokinetics were observed.
MANAGEMENT: Oral medications or mineral supplements that contain zinc are recommended to be administered at least 3 hours after the cephalexin, ceftibuten or cephradine dose.
References (3)
- Ding Y, Jia Y, Li F, et al. (2011) "The Effect of Staggered Administration of Zinc Sulfate on the Pharmacokinetics of Oral Cephalexin*" Br J Clin Pharmacol, 73, p. 422-7
- World Health Organization (2020) WHO Public Assessment Reports (WHOPARs) https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars
- Okamura M, Terada t, KatsuraT, Saito H, Inui K (2003) "Inhibitory effect of zinc on PEPT1-mediated transport of glycylsarcosine and beta-lactam antibiotics in human intestinal cell line Caco-2" Pharm Res, 20, p. 1389-93
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.